首页 > 最新文献

Pharmacy最新文献

英文 中文
Education for Healthcare Providers: Impact of Academic Detailing on Reducing Misinformation and Strengthening Influenza Vaccine Recommendations. 医疗保健提供者的教育:学术细节对减少错误信息和加强流感疫苗建议的影响。
IF 2 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-23 DOI: 10.3390/pharmacy12060188
Kimberly C McKeirnan, Megan E Giruzzi, Damianne C Brand, Nick R Giruzzi, Kavya Vaitla, Juliet Dang

Background: Recommendations from a trusted healthcare provider have been shown to be the most effective intervention for encouraging patients to be vaccinated. However, providers have reported feeling less prepared to address vaccination questions and having less time to discuss vaccines with patients than before the COVID-19 pandemic. Providers may benefit from a brief update about the available influenza vaccines and vaccination guidelines. Academic detailing is an evidence-based approach for preparing healthcare providers to discuss getting vaccinated with patients.

Methods: An academic detailing presentation was developed using influenza statistics, vaccination recommendations, and recent local and national immunization rate data. Academic detailing was conducted with physicians and community pharmacy personnel in Yakima County, Washington, between November 2023 and January 2024. Yakima County is designated as a medically underserved area due to a lack of providers. A pre-detailing survey was conducted to evaluate participant knowledge of current ACIP recommendations and gather opinions about local resident vaccination barriers. A post-detailing survey was conducted to gather participants' opinions about the value of detailing.

Results: Prior to the training, 73% of providers believed it was important to discuss influenza vaccination with patients, but only 52% felt confident in combating misinformation. Healthcare providers believed misinformation and vaccine hesitancy are the most common barriers for Yakima County patients, but recent survey results showed that online scheduling systems, long wait times, and limited appointment hours were the predominant issues reported locally. Two out of 12 community pharmacy personnel and zero resident physicians correctly named all three preferentially recommended influenza vaccines for patients 65 years and older. Overall, 96% of detailing participants reported that the session was valuable, 87% believed it would help them combat vaccine misinformation, and 65% reported planning to have more conversations with patients about influenza vaccination after participating.

Conclusion: Physicians and community pharmacy immunizers found the influenza vaccines academic detailing to be valuable. Staying up to date on vaccination guidelines can prepare providers to be confident in having informed conversations with patients about getting vaccinated.

背景:值得信赖的医疗保健提供者的建议已被证明是鼓励患者接种疫苗的最有效干预措施。然而,服务提供者报告说,与COVID-19大流行之前相比,他们对解决疫苗接种问题的准备不足,与患者讨论疫苗的时间也更少。提供人员可以从现有流感疫苗和疫苗接种指南的简短更新中获益。学术细节是一种以证据为基础的方法,用于准备医疗保健提供者与患者讨论接种疫苗。方法:利用流感统计数据、疫苗接种建议以及最近的地方和国家免疫接种率数据,制定了一份学术详细报告。学术细节是在2023年11月至2024年1月期间与华盛顿州亚基马县的医生和社区药房人员一起进行的。由于缺乏医疗服务提供者,亚基马县被指定为医疗服务不足的地区。进行了一项预先详细的调查,以评估参与者对当前ACIP建议的了解程度,并收集有关当地居民接种疫苗障碍的意见。我们进行了一项细节化后的调查,以收集参与者对细节化价值的看法。结果:在培训之前,73%的医疗服务提供者认为与患者讨论流感疫苗接种是重要的,但只有52%的人对打击错误信息有信心。医疗保健提供者认为,错误信息和疫苗犹豫是亚基马县患者最常见的障碍,但最近的调查结果显示,在线调度系统、漫长的等待时间和有限的预约时间是当地报告的主要问题。12名社区药房工作人员中有2名和0名住院医师正确说出65岁及以上患者优先推荐的所有三种流感疫苗。总体而言,96%的详细参与者报告说,会议是有价值的,87%的人认为这将有助于他们打击疫苗错误信息,65%的人报告说,计划在参加后与患者就流感疫苗接种进行更多的对话。结论:医生和社区药房免疫人员认为流感疫苗的学术详细资料是有价值的。保持最新的疫苗接种指南可以使提供者有信心与患者就接种疫苗进行知情的对话。
{"title":"Education for Healthcare Providers: Impact of Academic Detailing on Reducing Misinformation and Strengthening Influenza Vaccine Recommendations.","authors":"Kimberly C McKeirnan, Megan E Giruzzi, Damianne C Brand, Nick R Giruzzi, Kavya Vaitla, Juliet Dang","doi":"10.3390/pharmacy12060188","DOIUrl":"10.3390/pharmacy12060188","url":null,"abstract":"<p><strong>Background: </strong>Recommendations from a trusted healthcare provider have been shown to be the most effective intervention for encouraging patients to be vaccinated. However, providers have reported feeling less prepared to address vaccination questions and having less time to discuss vaccines with patients than before the COVID-19 pandemic. Providers may benefit from a brief update about the available influenza vaccines and vaccination guidelines. Academic detailing is an evidence-based approach for preparing healthcare providers to discuss getting vaccinated with patients.</p><p><strong>Methods: </strong>An academic detailing presentation was developed using influenza statistics, vaccination recommendations, and recent local and national immunization rate data. Academic detailing was conducted with physicians and community pharmacy personnel in Yakima County, Washington, between November 2023 and January 2024. Yakima County is designated as a medically underserved area due to a lack of providers. A pre-detailing survey was conducted to evaluate participant knowledge of current ACIP recommendations and gather opinions about local resident vaccination barriers. A post-detailing survey was conducted to gather participants' opinions about the value of detailing.</p><p><strong>Results: </strong>Prior to the training, 73% of providers believed it was important to discuss influenza vaccination with patients, but only 52% felt confident in combating misinformation. Healthcare providers believed misinformation and vaccine hesitancy are the most common barriers for Yakima County patients, but recent survey results showed that online scheduling systems, long wait times, and limited appointment hours were the predominant issues reported locally. Two out of 12 community pharmacy personnel and zero resident physicians correctly named all three preferentially recommended influenza vaccines for patients 65 years and older. Overall, 96% of detailing participants reported that the session was valuable, 87% believed it would help them combat vaccine misinformation, and 65% reported planning to have more conversations with patients about influenza vaccination after participating.</p><p><strong>Conclusion: </strong>Physicians and community pharmacy immunizers found the influenza vaccines academic detailing to be valuable. Staying up to date on vaccination guidelines can prepare providers to be confident in having informed conversations with patients about getting vaccinated.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11678551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AIHEMAF-P: An Innovative Healthcare Model for Atrial Fibrillation Patients. AIHEMAF-P:心房颤动患者的创新医疗模式
IF 2 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-15 DOI: 10.3390/pharmacy12060187
Raffaele La Regina, Pasquale Innelli, Fulvio Glisenti, Gianbattista Bollani, Eugenio Leopardi, Gian Franco Gensini, Savina Nodari, Giuseppe La Regina, Micaela La Regina, Francesco Gabbrielli

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias of clinical relevance and a major cause of cardiovascular morbidity and mortality. Following a diagnosis of AF, patients are directed towards therapy with anticoagulant drugs to reduce the thromboembolic risk and antiarrhythmics to control their cardiac rhythm, with periodic follow-up checks. Despite the great ease of handling these drugs, we soon realized the need for follow-up models that would allow the appropriateness and safety of these pharmacological treatments to be monitored over time. This pilot study was conducted at a rural pharmacy. The study comprised 47 patients (average age 71.22 years) with nonvalvular atrial fibrillation (68% being paroxysmal) on NOACs. Twenty percent of the enrolled subjects lived alone and fifty-four percent of the participants stated that they were not independent in managing their treatment. The primary aim was to describe the implementation and the outcomes of an innovative smart clinic model in which a local trained pharmacist is a case manager, and the patient carries out the required checks via telemedicine and point-of-care testing systems (POCT) under the service pharmacy regime; the results of the checks could be shared in real time with the attending general practitioner and the relevant specialist. The secondary aims of this study were to evaluate adherence to the planned controls, the prescriptive appropriateness of the dosages and drugs and adherence to the prescribed therapy, the occurrence of pharmacological problems linked to drug type interactions, the occurrence of hemorrhagic and/or thromboembolic complications, the acceptance by the general practitioners and/or the specialists of the reports made by the pharmacist on the subsequent actions undertaken, the economic and social impact of this model on the National Health Service and on the patient, and the impact on the quality perceived by the patients involved in this innovative monitoring process. Compliance with the planned checks was 93%. The dosage of the anticoagulant drug during enrollment was found to be inappropriate, without apparent clinical reasons, in 11% of the sample. Adherence to the anticoagulant therapy was found to be 98%. In total, 214 drug-drug interactions of varying clinical relevance were detected. No embolic events were detected; however, 13% of the sample reported a major hemorrhagic event, which came to light thanks to the close monitoring of hemoglobinemia. A total of 109 reports were made to the patients' referring doctors in relation to the summarized anomalies, and 84% were accepted by the referring clinicians. Therefore, community pharmacists and pharmacy services represent ideal actors and contexts that, when integrated into the care network, can really favor individual care plan adherence and achieve daily morbidity reductions and cost savings through proper disease control and the early diagnosis of complications.

心房颤动(AF)是临床上最常见的心律失常之一,也是心血管疾病发病率和死亡率的主要原因之一。诊断为房颤后,患者应接受抗凝药物治疗以降低血栓栓塞风险,并接受抗心律失常药物治疗以控制心律,并定期随访检查。尽管处理这些药物非常容易,但我们很快意识到需要后续模型,以便长期监测这些药物治疗的适当性和安全性。这项初步研究是在一家农村药房进行的。该研究包括47例服用NOACs的非瓣膜性心房颤动(68%为阵发性)患者(平均年龄71.22岁)。20%的受试者独自生活,54%的参与者表示他们在管理治疗方面并不独立。主要目的是描述一种创新的智能诊所模式的实施和结果,在这种模式中,当地训练有素的药剂师是病例管理人员,患者通过服务药房制度下的远程医疗和护理点测试系统(POCT)进行所需的检查;检查结果可以实时与主治全科医生和相关专家共享。本研究的次要目的是评估对计划控制的依从性,剂量和药物的处方性以及对处方治疗的依从性,与药物类型相互作用相关的药理学问题的发生,出血和/或血栓栓塞并发症的发生,全科医生和/或专家对药剂师所做的后续行动报告的接受程度。这一模式对国民保健服务和患者的经济和社会影响,以及对参与这一创新监测过程的患者所感知的质量的影响。计划检查的符合性为93%。在入组期间发现抗凝药物的剂量不合适,没有明显的临床原因,在11%的样本。抗凝治疗的依从性为98%。总共检测到214种不同临床相关性的药物-药物相互作用。未发现栓塞事件;然而,13%的样本报告了严重的出血事件,这要归功于对血红蛋白血症的密切监测。患者的转诊医生共收到109份报告,其中84%被转诊医生接受。因此,社区药剂师和药房服务代表了理想的参与者和环境,当整合到护理网络时,可以真正有利于个人护理计划的遵守,并通过适当的疾病控制和早期诊断并发症实现每日发病率降低和成本节约。
{"title":"AIHEMAF-P: An Innovative Healthcare Model for Atrial Fibrillation Patients.","authors":"Raffaele La Regina, Pasquale Innelli, Fulvio Glisenti, Gianbattista Bollani, Eugenio Leopardi, Gian Franco Gensini, Savina Nodari, Giuseppe La Regina, Micaela La Regina, Francesco Gabbrielli","doi":"10.3390/pharmacy12060187","DOIUrl":"10.3390/pharmacy12060187","url":null,"abstract":"<p><p>Atrial fibrillation (AF) is one of the most common cardiac arrhythmias of clinical relevance and a major cause of cardiovascular morbidity and mortality. Following a diagnosis of AF, patients are directed towards therapy with anticoagulant drugs to reduce the thromboembolic risk and antiarrhythmics to control their cardiac rhythm, with periodic follow-up checks. Despite the great ease of handling these drugs, we soon realized the need for follow-up models that would allow the appropriateness and safety of these pharmacological treatments to be monitored over time. This pilot study was conducted at a rural pharmacy. The study comprised 47 patients (average age 71.22 years) with nonvalvular atrial fibrillation (68% being paroxysmal) on NOACs. Twenty percent of the enrolled subjects lived alone and fifty-four percent of the participants stated that they were not independent in managing their treatment. The primary aim was to describe the implementation and the outcomes of an innovative smart clinic model in which a local trained pharmacist is a case manager, and the patient carries out the required checks via telemedicine and point-of-care testing systems (POCT) under the service pharmacy regime; the results of the checks could be shared in real time with the attending general practitioner and the relevant specialist. The secondary aims of this study were to evaluate adherence to the planned controls, the prescriptive appropriateness of the dosages and drugs and adherence to the prescribed therapy, the occurrence of pharmacological problems linked to drug type interactions, the occurrence of hemorrhagic and/or thromboembolic complications, the acceptance by the general practitioners and/or the specialists of the reports made by the pharmacist on the subsequent actions undertaken, the economic and social impact of this model on the National Health Service and on the patient, and the impact on the quality perceived by the patients involved in this innovative monitoring process. Compliance with the planned checks was 93%. The dosage of the anticoagulant drug during enrollment was found to be inappropriate, without apparent clinical reasons, in 11% of the sample. Adherence to the anticoagulant therapy was found to be 98%. In total, 214 drug-drug interactions of varying clinical relevance were detected. No embolic events were detected; however, 13% of the sample reported a major hemorrhagic event, which came to light thanks to the close monitoring of hemoglobinemia. A total of 109 reports were made to the patients' referring doctors in relation to the summarized anomalies, and 84% were accepted by the referring clinicians. Therefore, community pharmacists and pharmacy services represent ideal actors and contexts that, when integrated into the care network, can really favor individual care plan adherence and achieve daily morbidity reductions and cost savings through proper disease control and the early diagnosis of complications.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11678834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Objectively-Measured Sedentary Time and Self-Reported Prescription Medication Use Among Adults: A Pilot Study. 客观测量的久坐时间和成年人自我报告的处方药使用:一项初步研究。
IF 2 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-10 DOI: 10.3390/pharmacy12060186
Ciarra A Boyne, Tammie M Johnson, Lindsay P Toth, Michael R Richardson, James R Churilla

While previous research has linked physical activity (PA) with lower prescription medication consumption, limited evidence has investigated sedentary time (ST) as a major contributor to medication use, despite ST's known association with chronic disease and mortality risk, even when PA volume is considered. This study aimed to examine the independent associations between objectively measured ST, patterns of sedentary bouts, and self-reported prescription medication use among adults ≥25 years of age. Thirty-two participants reported the number and type of medications they were currently prescribed and wore an accelerometer continuously on their hip for seven days to detect their ST. Poisson regression analysis was used to assess how average daily ST, sedentary bout frequency, and sedentary bout duration influenced medication use. The results revealed a significant association between greater ST and higher medication consumption. Specifically, each additional hour of ST per day, each sedentary bout, and each one-minute increase in bout duration were linked to a 66% (PR 1.66; 95% CI 1.25-2.19; p < 0.001), 36% (PR 1.36; 95% CI 1.12-1.64; p < 0.01), and 9% (PR 1.09; 95% CI 1.03-1.16; p < 0.01) higher prevalence of prescription medications, respectively. These findings suggest that higher ST is associated with a greater prevalence of using prescription medications in adults.

尽管以往的研究将体力活动(PA)与较低的处方药用量联系在一起,但对久坐时间(ST)作为用药主要因素的调查证据却很有限,尽管久坐时间与慢性疾病和死亡风险有关,即使考虑到体力活动量也是如此。本研究旨在考察年龄≥25 岁的成年人客观测量的久坐时间、久坐模式和自我报告的处方药使用量之间的独立关联。32 名参与者报告了他们目前处方药的数量和类型,并连续 7 天在臀部佩戴加速度计以检测他们的 ST。研究人员使用泊松回归分析法评估了日均ST、久坐频率和久坐时间对药物使用的影响。结果显示,静坐时间越长,用药量越大,两者之间存在明显的关联。具体来说,每天ST时间每增加一小时、每次久坐和每次久坐时间每增加一分钟,处方药的使用率就分别增加66% (PR 1.66; 95% CI 1.25-2.19; p < 0.001)、36% (PR 1.36; 95% CI 1.12-1.64; p < 0.01) 和 9% (PR 1.09; 95% CI 1.03-1.16; p < 0.01)。这些结果表明,ST 越高,成人使用处方药的比例越高。
{"title":"Objectively-Measured Sedentary Time and Self-Reported Prescription Medication Use Among Adults: A Pilot Study.","authors":"Ciarra A Boyne, Tammie M Johnson, Lindsay P Toth, Michael R Richardson, James R Churilla","doi":"10.3390/pharmacy12060186","DOIUrl":"10.3390/pharmacy12060186","url":null,"abstract":"<p><p>While previous research has linked physical activity (PA) with lower prescription medication consumption, limited evidence has investigated sedentary time (ST) as a major contributor to medication use, despite ST's known association with chronic disease and mortality risk, even when PA volume is considered. This study aimed to examine the independent associations between objectively measured ST, patterns of sedentary bouts, and self-reported prescription medication use among adults ≥25 years of age. Thirty-two participants reported the number and type of medications they were currently prescribed and wore an accelerometer continuously on their hip for seven days to detect their ST. Poisson regression analysis was used to assess how average daily ST, sedentary bout frequency, and sedentary bout duration influenced medication use. The results revealed a significant association between greater ST and higher medication consumption. Specifically, each additional hour of ST per day, each sedentary bout, and each one-minute increase in bout duration were linked to a 66% (PR 1.66; 95% CI 1.25-2.19; <i>p</i> < 0.001), 36% (PR 1.36; 95% CI 1.12-1.64; <i>p</i> < 0.01), and 9% (PR 1.09; 95% CI 1.03-1.16; <i>p</i> < 0.01) higher prevalence of prescription medications, respectively. These findings suggest that higher ST is associated with a greater prevalence of using prescription medications in adults.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11677380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rationale and Logistics of Continuous Infusion Cephalosporin Antibiotics. 头孢菌素类抗生素持续输注的理论基础和物流。
IF 2 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-05 DOI: 10.3390/pharmacy12060185
Abbie L Blunier, R Jake Crocker, Rachel Foster, Stephanie S May, Caroline E Powers, P Brandon Bookstaver

Cephalosporins have traditionally been administered as an intermittent infusion. With the knowledge that cephalosporins demonstrate a time-dependent pharmacodynamic profile, administration via continuous infusion may provide more effective antibiotic exposure for successful therapy. Proposed benefits of administration via continuous infusion include less IV manipulation, decreased potential for antibiotic resistance, and potential cost savings. The objective of this review was to provide a detailed assessment of available evidence for the use of continuous infusion cephalosporins and practical dosing and administration recommendations. Studies were gathered and assessed for inclusion via a literature search of PubMed and Ovid MEDLINE using mesh terms ["continuous infusion" and "cephalosporin"], "intermittent infusion", ["intermittent versus continuous" and "cephalosporin"], "continuous infusion cephalosporin", as well as specific drug names. References from included studies were also evaluated for inclusion. Data which compared the two administration methods (continuous infusion vs. intermittent infusion) were evaluated. Thirty-five studies were analyzed among several cephalosporins with variable delivery. Dosing regimens utilized in the selected studies were assessed with known compatibility and stability data and further summarized.

头孢菌素传统上是间歇性输注。由于了解到头孢菌素具有时间依赖性的药效学特征,通过持续输注给药可能为成功治疗提供更有效的抗生素暴露。建议通过持续输注给药的好处包括减少静脉操作,降低潜在的抗生素耐药性,以及潜在的成本节约。本综述的目的是对持续输注头孢菌素的使用以及实际剂量和给药建议的现有证据进行详细评估。通过PubMed和Ovid MEDLINE的文献检索,使用网格术语[“连续输注”和“头孢菌素”]、“间歇输注”、[间歇与连续输注]和“头孢菌素”]、“连续输注头孢菌素”以及特定药物名称,收集和评估研究。纳入研究的参考文献也被评估纳入。比较两种给药方法(连续输注与间歇输注)的数据进行了评估。35项研究分析了几种不同递送的头孢菌素。根据已知的相容性和稳定性数据对所选研究中使用的给药方案进行评估,并进一步总结。
{"title":"Rationale and Logistics of Continuous Infusion Cephalosporin Antibiotics.","authors":"Abbie L Blunier, R Jake Crocker, Rachel Foster, Stephanie S May, Caroline E Powers, P Brandon Bookstaver","doi":"10.3390/pharmacy12060185","DOIUrl":"10.3390/pharmacy12060185","url":null,"abstract":"<p><p>Cephalosporins have traditionally been administered as an intermittent infusion. With the knowledge that cephalosporins demonstrate a time-dependent pharmacodynamic profile, administration via continuous infusion may provide more effective antibiotic exposure for successful therapy. Proposed benefits of administration via continuous infusion include less IV manipulation, decreased potential for antibiotic resistance, and potential cost savings. The objective of this review was to provide a detailed assessment of available evidence for the use of continuous infusion cephalosporins and practical dosing and administration recommendations. Studies were gathered and assessed for inclusion via a literature search of PubMed and Ovid MEDLINE using mesh terms [\"continuous infusion\" and \"cephalosporin\"], \"intermittent infusion\", [\"intermittent versus continuous\" and \"cephalosporin\"], \"continuous infusion cephalosporin\", as well as specific drug names. References from included studies were also evaluated for inclusion. Data which compared the two administration methods (continuous infusion vs. intermittent infusion) were evaluated. Thirty-five studies were analyzed among several cephalosporins with variable delivery. Dosing regimens utilized in the selected studies were assessed with known compatibility and stability data and further summarized.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11678214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Pharmacist-Led Collaboration of Multiple Clinical Professions Model Focusing on Continuity of Pharmacotherapy: Japanese Version of the Lund Integrated Medicines Management (LIMM) Model. 以临床药师为主导的多临床专业合作模式,专注于药物治疗的连续性:隆德综合药物管理(LIMM)模式的日本版本。
IF 2 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-05 DOI: 10.3390/pharmacy12060184
Rie Sato, Syuichi Aoshima, Tommy Eriksson

(1) Background: In general, it is known that continuity of care can contribute to an increase in patient satisfaction, reduce health care costs, and improve patient outcomes. A guarantee of continuity in pharmacotherapy is a big challenge facing Japanese health care as a system that encourages cooperation/collaboration for pharmacists with other health care professions is currently lacking. (2) Method: This is a narrative review. (3) Results: The Lund Integrated Medicine Management (LIMM) model describes a systematic approach to individuals and was developed in Sweden to optimize pharmacotherapy among elderly inpatients. The aim of the LIMM model is to provide patients with continuous pharmacotherapy at different levels of care. The LIMM model, in which a clinical pharmacist is the catalyst and leads other health care professions in completing the process, has the potential to reduce potentially inappropriate prescriptions, reduce rehospitalization risk, unscheduled hospital revisits due to problems related to medications, reduce total medical expenditure, and provide a comprehensive understanding of patients' conditions of taking medicine. (4) Conclusions: Introducing a framework such as Sweden's LIMM model, anchored by clinical pharmacists, could provide a good opportunity to promote collaborations among different health care professionals and improve continuity in pharmacotherapy.

(1)背景:一般来说,连续性护理有助于提高患者满意度,降低医疗保健成本,改善患者预后。保证药物治疗的连续性是日本卫生保健面临的一个巨大挑战,因为目前缺乏鼓励药剂师与其他卫生保健专业人员合作的系统。(2)方法:这是一个叙述性的回顾。(3)结果:隆德综合医学管理(Lund Integrated Medicine Management, LIMM)模型描述了一种针对个体的系统方法,该模型由瑞典开发,用于优化老年住院患者的药物治疗。LIMM模型的目的是在不同的护理水平上为患者提供持续的药物治疗。在LIMM模式中,临床药剂师是催化剂,并领导其他医疗保健专业人员完成这一过程,这一模式有可能减少潜在的不适当处方,降低再住院风险,减少因药物相关问题而非计划的医院复诊,减少医疗总支出,并提供对患者服药情况的全面了解。(4)结论:以临床药师为主体,引入瑞典的LIMM模式等框架,可以促进不同医疗专业人员之间的合作,提高药物治疗的连续性。
{"title":"Clinical Pharmacist-Led Collaboration of Multiple Clinical Professions Model Focusing on Continuity of Pharmacotherapy: Japanese Version of the Lund Integrated Medicines Management (LIMM) Model.","authors":"Rie Sato, Syuichi Aoshima, Tommy Eriksson","doi":"10.3390/pharmacy12060184","DOIUrl":"10.3390/pharmacy12060184","url":null,"abstract":"<p><p>(1) Background: In general, it is known that continuity of care can contribute to an increase in patient satisfaction, reduce health care costs, and improve patient outcomes. A guarantee of continuity in pharmacotherapy is a big challenge facing Japanese health care as a system that encourages cooperation/collaboration for pharmacists with other health care professions is currently lacking. (2) Method: This is a narrative review. (3) Results: The Lund Integrated Medicine Management (LIMM) model describes a systematic approach to individuals and was developed in Sweden to optimize pharmacotherapy among elderly inpatients. The aim of the LIMM model is to provide patients with continuous pharmacotherapy at different levels of care. The LIMM model, in which a clinical pharmacist is the catalyst and leads other health care professions in completing the process, has the potential to reduce potentially inappropriate prescriptions, reduce rehospitalization risk, unscheduled hospital revisits due to problems related to medications, reduce total medical expenditure, and provide a comprehensive understanding of patients' conditions of taking medicine. (4) Conclusions: Introducing a framework such as Sweden's LIMM model, anchored by clinical pharmacists, could provide a good opportunity to promote collaborations among different health care professionals and improve continuity in pharmacotherapy.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11679876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Latvian Healthcare Professionals' Self-Reported Knowledge, Attitudes, and Behaviors Related to Pregnancy Prevention Program Materials for Valproate-Containing Medicines. 拉脱维亚卫生保健专业人员自我报告的知识、态度和行为与含丙戊酸药物的预防怀孕计划材料有关。
IF 2 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-04 DOI: 10.3390/pharmacy12060182
Milana Špoģe, Mirdza Kursīte, Elita Poplavska

Background: Valproates are recognized for their significant teratogenic risks, which can lead to physical defects and developmental disorders when used during pregnancy. To mitigate these risks, the Pregnancy Prevention Program (PPP) was developed by European regulators for patients and healthcare professionals (HCPs). Despite the crucial nature of this program, the implementation of the PPP does not appear to be fully effective. This situation highlights the need for a deeper understanding of HCPs' knowledge, attitudes, and behaviors regarding the PPP.

Methods: A cross-sectional study using anonymous electronic questionnaires was conducted. The questionnaires were developed by a board of experts from eight different EU countries and were distributed among prescribers (general practitioners (GPs), neurologists, and psychiatrists) and pharmacists. Descriptive statistics were used to analyze the obtained data on participants' knowledge, attitudes, and behaviors regarding the prescribing and dispensing of valproate-containing medicines to women of reproductive age, as well as the impact of PPP materials on their work.

Results: The study results indicate that while HCPs in Latvia are generally aware of valproate teratogenic risks, significant gaps remain in the implementation of the PPP. A considerable number of both prescribers and pharmacists expressed the belief that they are not responsible for educating patients about the PPP, attributing this responsibility to other specialists. Furthermore, barriers such as a lack of time and accessible materials were identified.

Conclusions: The roles and responsibilities of HCPs should be clearly defined to improve adherence to the PPP. Further research is needed to assess prescription and dispensing strategies, as well as HCPs' attitudes toward the PPP. Additionally, re-evaluating and enhancing the accessibility of PPP materials is essential in effective risk management and better patient care.

背景:丙戊酸盐被认为具有显著的致畸风险,妊娠期间使用丙戊酸盐可导致身体缺陷和发育障碍。为了减轻这些风险,欧洲监管机构为患者和医疗保健专业人员(HCPs)制定了妊娠预防计划(PPP)。尽管这一项目具有至关重要的性质,但PPP的实施似乎并不完全有效。这种情况突出表明,需要更深入地了解医护人员在公私合作方面的知识、态度和行为。方法:采用匿名电子问卷进行横断面研究。问卷是由来自八个不同欧盟国家的专家委员会制定的,并在处方医师(全科医生(gp)、神经科医生和精神科医生)和药剂师中分发。采用描述性统计的方法对获得的数据进行分析,包括被调查对象对育龄妇女丙戊酸类药物的处方和配药的知识、态度和行为,以及PPP材料对其工作的影响。结果:研究结果表明,虽然拉脱维亚的HCPs普遍意识到丙戊酸致畸风险,但在PPP的实施方面仍存在重大差距。相当多的开处方者和药剂师都表示,他们没有责任对患者进行PPP教育,并将这一责任归咎于其他专家。此外,还确定了缺乏时间和可获得材料等障碍。结论:应明确医护人员的角色和责任,以提高对PPP的依从性。需要进一步的研究来评估处方和配药策略,以及医护人员对PPP的态度。此外,重新评估和提高PPP材料的可及性对于有效的风险管理和更好的患者护理至关重要。
{"title":"Latvian Healthcare Professionals' Self-Reported Knowledge, Attitudes, and Behaviors Related to Pregnancy Prevention Program Materials for Valproate-Containing Medicines.","authors":"Milana Špoģe, Mirdza Kursīte, Elita Poplavska","doi":"10.3390/pharmacy12060182","DOIUrl":"10.3390/pharmacy12060182","url":null,"abstract":"<p><strong>Background: </strong>Valproates are recognized for their significant teratogenic risks, which can lead to physical defects and developmental disorders when used during pregnancy. To mitigate these risks, the Pregnancy Prevention Program (PPP) was developed by European regulators for patients and healthcare professionals (HCPs). Despite the crucial nature of this program, the implementation of the PPP does not appear to be fully effective. This situation highlights the need for a deeper understanding of HCPs' knowledge, attitudes, and behaviors regarding the PPP.</p><p><strong>Methods: </strong>A cross-sectional study using anonymous electronic questionnaires was conducted. The questionnaires were developed by a board of experts from eight different EU countries and were distributed among prescribers (general practitioners (GPs), neurologists, and psychiatrists) and pharmacists. Descriptive statistics were used to analyze the obtained data on participants' knowledge, attitudes, and behaviors regarding the prescribing and dispensing of valproate-containing medicines to women of reproductive age, as well as the impact of PPP materials on their work.</p><p><strong>Results: </strong>The study results indicate that while HCPs in Latvia are generally aware of valproate teratogenic risks, significant gaps remain in the implementation of the PPP. A considerable number of both prescribers and pharmacists expressed the belief that they are not responsible for educating patients about the PPP, attributing this responsibility to other specialists. Furthermore, barriers such as a lack of time and accessible materials were identified.</p><p><strong>Conclusions: </strong>The roles and responsibilities of HCPs should be clearly defined to improve adherence to the PPP. Further research is needed to assess prescription and dispensing strategies, as well as HCPs' attitudes toward the PPP. Additionally, re-evaluating and enhancing the accessibility of PPP materials is essential in effective risk management and better patient care.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11679773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights from a National Survey on Controlled Substance Diversion Practices in U.S. Hospital Pharmacies: Opportunities for Enhanced Surveillance and Compliance. 来自美国医院药房管制物质转移实践的全国调查的见解:加强监督和遵守的机会。
IF 2 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-04 DOI: 10.3390/pharmacy12060183
Samantha S Bastow, Eric P Borrelli, Julia D Lucaci, Heather Nelkin, April Graves, Amanda Hays

This study explored controlled substance (CS) diversion surveillance practices within hospital pharmacies across the United States. A survey with questions based on published CS diversion risk points was conducted in May 2024. A total of 66 participants from 31 states responded, with 54.5% from single facilities and the remaining from health systems. Most respondents were pharmacy directors, managers, or those in dedicated drug diversion roles. Over 70% have dedicated surveillance teams and use drug diversion software. Results highlight variation in practices, with larger institutions generally showing better compliance. Compliance in procurement and receiving was high for access measures; however, auditing of processes was lower. The lowest procurement compliance was in monitoring periodic automatic replacement (PAR) levels and validating orders with wholesalers. Storage practices showed high compliance in deploying cameras, but low compliance in monitoring them. Dispensing practices had high compliance for restricting CS in automated dispensing cabinets, but low incidence of witness verification during stocking. Waste and disposal practices were well-followed, but training on detecting potential signs of medication tampering was less common. The survey highlights that while strategies to prevent CS diversion exist, their implementation varies. Enhancing monitoring, auditing, and training is essential to strengthen diversion prevention efforts in hospital pharmacies.

本研究探讨控制物质(CS)转移监测实践在医院药房在美国各地。2024年5月,根据已公布的CS分流风险点进行了问卷调查。来自31个州的66名参与者做出了回应,其中54.5%来自单一机构,其余来自卫生系统。大多数受访者是药房主任、经理或专门从事药物转移工作的人员。超过70%的人有专门的监测小组,并使用毒品转移软件。结果突出了实践中的差异,较大的机构通常表现出更好的遵从性。采购和接收方面对获取措施的遵守程度很高;但是,对流程的审计较低。最低的采购合规是监测定期自动更换(PAR)水平和与批发商确认订单。存储实践在部署摄像机方面表现出较高的遵从性,但在监控摄像机方面表现出较低的遵从性。在自动配药柜中限制CS的配药实践具有很高的符合性,但在库存期间证人验证的发生率较低。废物和处理做法得到了很好的遵循,但关于检测药物篡改潜在迹象的培训却不太常见。调查强调,虽然存在防止CS转移的策略,但其实施情况各不相同。加强监测、审计和培训对加强医院药房的分流预防工作至关重要。
{"title":"Insights from a National Survey on Controlled Substance Diversion Practices in U.S. Hospital Pharmacies: Opportunities for Enhanced Surveillance and Compliance.","authors":"Samantha S Bastow, Eric P Borrelli, Julia D Lucaci, Heather Nelkin, April Graves, Amanda Hays","doi":"10.3390/pharmacy12060183","DOIUrl":"10.3390/pharmacy12060183","url":null,"abstract":"<p><p>This study explored controlled substance (CS) diversion surveillance practices within hospital pharmacies across the United States. A survey with questions based on published CS diversion risk points was conducted in May 2024. A total of 66 participants from 31 states responded, with 54.5% from single facilities and the remaining from health systems. Most respondents were pharmacy directors, managers, or those in dedicated drug diversion roles. Over 70% have dedicated surveillance teams and use drug diversion software. Results highlight variation in practices, with larger institutions generally showing better compliance. Compliance in procurement and receiving was high for access measures; however, auditing of processes was lower. The lowest procurement compliance was in monitoring periodic automatic replacement (PAR) levels and validating orders with wholesalers. Storage practices showed high compliance in deploying cameras, but low compliance in monitoring them. Dispensing practices had high compliance for restricting CS in automated dispensing cabinets, but low incidence of witness verification during stocking. Waste and disposal practices were well-followed, but training on detecting potential signs of medication tampering was less common. The survey highlights that while strategies to prevent CS diversion exist, their implementation varies. Enhancing monitoring, auditing, and training is essential to strengthen diversion prevention efforts in hospital pharmacies.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11676067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-Performance Liquid Chromatography with DAD Detection for the Determination of Cannabinoids in Commercial Veterinary CBD Oil. 高效液相色谱- DAD法测定市售兽用CBD油中大麻素含量。
IF 2 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-02 DOI: 10.3390/pharmacy12060181
Zehra Hajrulai-Musliu, Elizabeta Dimitreska Stojkovikj, Dimitar Gusheski, Dea Musliu, Daniel Velkovski

The study highlights the need for quality control in evaluating medicinal plant products, especially CBD oils, before market release. Due to varying regulatory requirements, product labeling can sometimes be misleading, especially regarding cannabinoid concentrations such as CBD and THC. This research focused on developing a validated high-performance liquid chromatography (HPLC) method for accurately identifying and quantifying key cannabinoids in Commercial Veterinary CBD Oil. The main compounds identified included Cannabidivarin (CBDV), Cannabidiolic Acid (CBD-A), Cannabigerolic Acid (CBG-A), Cannabigerol (CBG), Cannabidiol (CBD), Tetrahydrocannabivarin (THCV), Cannabinol (CBN), ∆9-Tetrahydrocannabinol (d9-THC) ∆8-Tetrahydrocannabinol (d8-THC), Cannabicyclol (CBL), Cannabichromene (CBC), and Tetrahydrocannabinolic Acid (THCA), determined in line with the International Conference on Harmonization's (ICH) guidelines. The method was validated for linearity, accuracy, precision, limit of detection (LOD), and limit of quantitation (LOQ). It was determined to be linear, with a correlation coefficient (R²) > 0.999. The LOD and LOQ values calculated from the calibration curve ranged from 0.05 to 0.13 and 0.50 to 0.61 µg/mL, respectively. The method also exhibited acceptable precision, with relative standard deviation values lower than or equal to 2%. The method's accuracy was assessed through recovery percentages and fell within an acceptable range of 98-102 if the RSD was 2%. This study's rigorous methodology and comprehensive findings significantly contribute to cannabinoid analysis. This validated protocol was used to analyze cannabinoids in 14 commercial veterinary CBD oil products from the Republic of North Macedonia. The performance parameters demonstrated that the method is reliable for quantitatively measuring cannabinoids in CBD oil. The analysis showed that the cannabinoid levels in the products were consistent with the manufacturers' declared specifications, with no significant discrepancies in labeling.

该研究强调了在药用植物产品,特别是CBD油上市前对其进行质量控制的必要性。由于不同的监管要求,产品标签有时会产生误导,特别是关于大麻素浓度,如CBD和四氢大麻酚。本研究的重点是建立一种高效液相色谱(HPLC)方法来准确鉴定和定量商业用CBD油中的关键大麻素。鉴定的主要化合物包括大麻二酚(CBDV)、大麻二酸(CBD- a)、大麻二酸(CBG- a)、大麻酚(CBG)、大麻二酚(CBD)、四氢大麻酚(THCV)、大麻酚(CBN)、∆9-四氢大麻酚(d9-THC)、大麻环酚(CBL)、大麻二酚(CBC)和四氢大麻酚酸(THCA),这些化合物是根据国际协调会议(ICH)的指导方针确定的。对方法进行了线性度、准确度、精密度、检出限和定量限的验证。结果表明,两者呈线性关系,相关系数(R²)为0 0.999。定量限和定量限分别为0.05 ~ 0.13µg/mL和0.50 ~ 0.61µg/mL。该方法也具有可接受的精度,相对标准偏差值小于或等于2%。该方法的准确度通过回收率进行评估,如果RSD为2%,则在98-102的可接受范围内。这项研究严谨的方法和全面的发现显著有助于大麻素分析。该验证方案用于分析来自北马其顿共和国的14种商业兽药CBD油产品中的大麻素。实验结果表明,该方法可用于CBD油中大麻素的定量测定。分析表明,产品中的大麻素含量与制造商声明的规格一致,标签上没有显着差异。
{"title":"High-Performance Liquid Chromatography with DAD Detection for the Determination of Cannabinoids in Commercial Veterinary CBD Oil.","authors":"Zehra Hajrulai-Musliu, Elizabeta Dimitreska Stojkovikj, Dimitar Gusheski, Dea Musliu, Daniel Velkovski","doi":"10.3390/pharmacy12060181","DOIUrl":"10.3390/pharmacy12060181","url":null,"abstract":"<p><p>The study highlights the need for quality control in evaluating medicinal plant products, especially CBD oils, before market release. Due to varying regulatory requirements, product labeling can sometimes be misleading, especially regarding cannabinoid concentrations such as CBD and THC. This research focused on developing a validated high-performance liquid chromatography (HPLC) method for accurately identifying and quantifying key cannabinoids in Commercial Veterinary CBD Oil. The main compounds identified included Cannabidivarin (CBDV), Cannabidiolic Acid (CBD-A), Cannabigerolic Acid (CBG-A), Cannabigerol (CBG), Cannabidiol (CBD), Tetrahydrocannabivarin (THCV), Cannabinol (CBN), ∆<sup>9</sup>-Tetrahydrocannabinol (d9-THC) ∆8-Tetrahydrocannabinol (d8-THC), Cannabicyclol (CBL), Cannabichromene (CBC), and Tetrahydrocannabinolic Acid (THCA), determined in line with the International Conference on Harmonization's (ICH) guidelines. The method was validated for linearity, accuracy, precision, limit of detection (LOD), and limit of quantitation (LOQ). It was determined to be linear, with a correlation coefficient (R²) > 0.999. The LOD and LOQ values calculated from the calibration curve ranged from 0.05 to 0.13 and 0.50 to 0.61 µg/mL, respectively. The method also exhibited acceptable precision, with relative standard deviation values lower than or equal to 2%. The method's accuracy was assessed through recovery percentages and fell within an acceptable range of 98-102 if the RSD was 2%. This study's rigorous methodology and comprehensive findings significantly contribute to cannabinoid analysis. This validated protocol was used to analyze cannabinoids in 14 commercial veterinary CBD oil products from the Republic of North Macedonia. The performance parameters demonstrated that the method is reliable for quantitatively measuring cannabinoids in CBD oil. The analysis showed that the cannabinoid levels in the products were consistent with the manufacturers' declared specifications, with no significant discrepancies in labeling.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11677526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addition of Bevacizumab to Chemotherapy and Its Impact on Clinical Efficacy in Cervical Cancer: A Systematic Review and Meta-Analysis. 贝伐单抗加入化疗及其对宫颈癌临床疗效的影响:系统回顾和荟萃分析
IF 2 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-01 DOI: 10.3390/pharmacy12060180
Aleena Shahzad, Anees Ur Rehman, Tehnia Naz, Muhammad Fawad Rasool, Alisha Saeed, Saba Rasheed, Sadia Shakeel, Saleh Karamah Al-Tamimi, Rabia Hussain

Background and Objectives: Cervical cancer is the third leading cause of cancer-related mortality in females. One of the most successful therapeutic modalities to date is suppressing vascular endothelial growth factor (VEGF)-mediated angiogenesis. Bevacizumab is a monoclonal antibody that targets VEGF-A. The outcomes for cervical cancer patients treated with bevacizumab in combination with platinum-based chemotherapy have been explored in several studies. This study aimed to assess the impact of bevacizumab on progression-free survival (PFS) and overall survival (OS) in patients with metastatic cervical cancer. Materials and Methods: This systematic review was registered in PROSPERO (CRD42023456755). Following PRISMA guidelines, a comprehensive literature search on PubMed and Google Scholar identified 28 studies meeting the inclusion criteria. The outcomes of interest were PFS and OS. The statistical analysis computed hazard ratios (HRs) with 95% confidence intervals (CIs). The study also included a subgroup analysis by cervical cancer stage. Results: The pooled analysis revealed that bevacizumab-based therapy significantly improved both PFS with HR 0.77 (95% CI: 0.58-0.96; p < 0.01; I2 = 58%) and OS with HR 0.63 (95% CI: 0.45-0.89; p < 0.01; I2 = 41%) in cervical cancer patients. Subgroup analysis by stage of cervical cancer demonstrated better efficacy of bevacizumab in metastatic stage IVB cervical cancer patients indicated by HR for PFS (0.69, 95% CI: 0.54-0.79; p < 0.01) and HR for OS (0.57, 95% CI: 0.46-0.73; p < 0.01). Conclusions: Bevacizumab exhibits a significant increase in PFS and OS, underscoring the efficacy of anti-angiogenesis therapy in cervical cancer, particularly in stage IVB metastatic cervical cancer patients.

背景和目的:宫颈癌是女性癌症相关死亡的第三大原因。迄今为止最成功的治疗方式之一是抑制血管内皮生长因子(VEGF)介导的血管生成。贝伐单抗是一种靶向VEGF-A的单克隆抗体。一些研究已经探讨了贝伐单抗联合铂基化疗治疗宫颈癌患者的结果。本研究旨在评估贝伐单抗对转移性宫颈癌患者的无进展生存期(PFS)和总生存期(OS)的影响。材料和方法:本系统综述已在PROSPERO注册(CRD42023456755)。根据PRISMA指南,在PubMed和b谷歌Scholar上进行了全面的文献检索,确定了28项符合纳入标准的研究。关注的结果是PFS和OS。统计分析计算风险比(hr), 95%置信区间(ci)。该研究还包括子宫颈癌分期的亚组分析。结果:合并分析显示,以贝伐单抗为基础的治疗显著改善了两种PFS, HR为0.77 (95% CI: 0.58-0.96;P < 0.01;I2 = 58%)和OS的危险度为0.63 (95% CI: 0.45-0.89;P < 0.01;I2 = 41%)。宫颈癌分期亚组分析显示,贝伐单抗在转移期IVB宫颈癌患者中疗效更好(HR为PFS) (0.69, 95% CI: 0.54-0.79;p < 0.01)和OS的HR (0.57, 95% CI: 0.46-0.73;P < 0.01)。结论:贝伐单抗可显著提高PFS和OS,强调抗血管生成治疗在宫颈癌,特别是IVB期转移性宫颈癌患者中的疗效。
{"title":"Addition of Bevacizumab to Chemotherapy and Its Impact on Clinical Efficacy in Cervical Cancer: A Systematic Review and Meta-Analysis.","authors":"Aleena Shahzad, Anees Ur Rehman, Tehnia Naz, Muhammad Fawad Rasool, Alisha Saeed, Saba Rasheed, Sadia Shakeel, Saleh Karamah Al-Tamimi, Rabia Hussain","doi":"10.3390/pharmacy12060180","DOIUrl":"10.3390/pharmacy12060180","url":null,"abstract":"<p><p><i>Background and Objectives</i>: Cervical cancer is the third leading cause of cancer-related mortality in females. One of the most successful therapeutic modalities to date is suppressing vascular endothelial growth factor (VEGF)-mediated angiogenesis. Bevacizumab is a monoclonal antibody that targets VEGF-A. The outcomes for cervical cancer patients treated with bevacizumab in combination with platinum-based chemotherapy have been explored in several studies. This study aimed to assess the impact of bevacizumab on progression-free survival (PFS) and overall survival (OS) in patients with metastatic cervical cancer. <i>Materials and Methods</i>: This systematic review was registered in PROSPERO (CRD42023456755). Following PRISMA guidelines, a comprehensive literature search on PubMed and Google Scholar identified 28 studies meeting the inclusion criteria. The outcomes of interest were PFS and OS. The statistical analysis computed hazard ratios (HRs) with 95% confidence intervals (CIs). The study also included a subgroup analysis by cervical cancer stage. <i>Results</i>: The pooled analysis revealed that bevacizumab-based therapy significantly improved both PFS with HR 0.77 (95% CI: 0.58-0.96; <i>p</i> < 0.01; I<sup>2</sup> = 58%) and OS with HR 0.63 (95% CI: 0.45-0.89; <i>p</i> < 0.01; I<sup>2</sup> = 41%) in cervical cancer patients. Subgroup analysis by stage of cervical cancer demonstrated better efficacy of bevacizumab in metastatic stage IVB cervical cancer patients indicated by HR for PFS (0.69, 95% CI: 0.54-0.79; <i>p</i> < 0.01) and HR for OS (0.57, 95% CI: 0.46-0.73; <i>p</i> < 0.01). <i>Conclusions</i>: Bevacizumab exhibits a significant increase in PFS and OS, underscoring the efficacy of anti-angiogenesis therapy in cervical cancer, particularly in stage IVB metastatic cervical cancer patients.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11677453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current Situation for Pharmacists in Japanese Veterinary Medicine: Exploring the Pharmaceutical Needs and Challenges of Veterinary Staff to Facilitate Collaborative Veterinary Care. 日本兽药药师的现状:探讨兽药人员的药物需求和挑战,促进兽药协同护理。
IF 2 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-29 DOI: 10.3390/pharmacy12060179
Taisuke Konno, Hiroyuki Suzuki, Naoto Suzuki, Kouji Okada, Yosuke Nishikawa, Daisuke Kikuchi, Hitoshi Nakamura, Yuriko Murai

While veterinary pharmacy is common overseas, it has yet to gain traction in Japan. To clarify the actual situation in Japan, two surveys were conducted, targeting 4017 facilities (2000 pharmacies/drug stores, 2000 veterinary medical facilities, and 17 university-affiliated veterinary hospitals). We received 324 responses from pharmacy staff and 217 from veterinary hospital staff. Pharmacists were involved in drug therapy for companion animals either via direct discussion with veterinarians or by referrals for prescriptions from veterinarians (11 respondents). Veterinary staff and pharmacists showed a disparity regarding pharmacists' involvement in companion animal healthcare. Veterinary staff wanted pharmacists to provide pharmaceutical guidance, perform audits, supply drug information, and prepare drugs. Strong demand (72.2% of the veterinary staff) existed for consultations with pharmacists regarding medication issues. Veterinary medicine has evolved to meet the demand for the advanced care of companion animals. Veterinary staff have diverse and substantial requests for pharmacists. Integrating the expertise of both veterinary staff and pharmacists may facilitate a team-based approach to veterinary medicine and improve the quality of care for companion animals. Tailoring approaches to suit Japan's unique circumstances and creating a conducive environment for effective communication between pharmacists and veterinary staff are pivotal for advancing veterinary pharmacy in Japan.

虽然兽医药房在海外很常见,但在日本尚未获得关注。为了澄清日本的实际情况,进行了两次调查,调查对象是4017家机构(2000家药房/药店、2000家兽医机构和17家大学附属兽医医院)。我们收到了324份药房工作人员和217份兽医院工作人员的回复。药剂师参与伴侣动物的药物治疗,要么与兽医直接讨论,要么从兽医那里获得处方(11名受访者)。兽医工作人员和药剂师在参与伴侣动物保健方面表现出差异。兽医工作人员希望药剂师提供药学指导、执行审核、提供药物信息和配制药物。就用药问题向药剂师咨询的需求很大(占兽医工作人员的72.2%)。兽医已经发展到满足对伴侣动物高级护理的需求。兽医工作人员对药剂师有各种各样的大量要求。整合兽医工作人员和药剂师的专业知识可以促进以团队为基础的兽医方法,并提高对伴侣动物的护理质量。根据日本的独特情况量身定制方法,并为药剂师和兽医工作人员之间的有效沟通创造有利的环境,是推动日本兽医药学发展的关键。
{"title":"Current Situation for Pharmacists in Japanese Veterinary Medicine: Exploring the Pharmaceutical Needs and Challenges of Veterinary Staff to Facilitate Collaborative Veterinary Care.","authors":"Taisuke Konno, Hiroyuki Suzuki, Naoto Suzuki, Kouji Okada, Yosuke Nishikawa, Daisuke Kikuchi, Hitoshi Nakamura, Yuriko Murai","doi":"10.3390/pharmacy12060179","DOIUrl":"10.3390/pharmacy12060179","url":null,"abstract":"<p><p>While veterinary pharmacy is common overseas, it has yet to gain traction in Japan. To clarify the actual situation in Japan, two surveys were conducted, targeting 4017 facilities (2000 pharmacies/drug stores, 2000 veterinary medical facilities, and 17 university-affiliated veterinary hospitals). We received 324 responses from pharmacy staff and 217 from veterinary hospital staff. Pharmacists were involved in drug therapy for companion animals either via direct discussion with veterinarians or by referrals for prescriptions from veterinarians (11 respondents). Veterinary staff and pharmacists showed a disparity regarding pharmacists' involvement in companion animal healthcare. Veterinary staff wanted pharmacists to provide pharmaceutical guidance, perform audits, supply drug information, and prepare drugs. Strong demand (72.2% of the veterinary staff) existed for consultations with pharmacists regarding medication issues. Veterinary medicine has evolved to meet the demand for the advanced care of companion animals. Veterinary staff have diverse and substantial requests for pharmacists. Integrating the expertise of both veterinary staff and pharmacists may facilitate a team-based approach to veterinary medicine and improve the quality of care for companion animals. Tailoring approaches to suit Japan's unique circumstances and creating a conducive environment for effective communication between pharmacists and veterinary staff are pivotal for advancing veterinary pharmacy in Japan.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11677796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pharmacy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1